Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor

Kayla Myers Chen,Daniel Grun,Brian Gautier,Shivaprasad Venkatesha,Michael Maddox,Ai-Hong Zhang,Peter Andersen

DOI: https://doi.org/10.1101/2024.01.29.577873

2024-02-01

Abstract:Myeloid cells are prevalent in solid cancers, but they frequently exhibit a pro-tumor phenotype, hindering cancer immunotherapy. Their abundance makes engineered myeloid cell therapy an intriguing approach to tackle challenges posed by solid cancers, such as tumor trafficking and infiltration along with tumor cell heterogenicity and immunosuppressive tumor microenvironment (TME). Solid cancers often upregulate the checkpoint molecule PD-L1 to evade immune responses. Thus, we devised an adoptive cell therapy strategy based on myeloid cells expressing a Chimeric Antigen Receptor (CAR)-like immune receptor (CARIR). The extracellular domain of CARIR is derived from the natural inhibitory receptor PD-1, while the intracellular domain(s) are derived from CD40 and/or CD3ξ. To assess the efficacy of CARIR-engineered myeloid cells, we conducted proof-of-principle experiments using co-culture and flow cytometry-based phagocytosis assays . Additionally, we employed a fully immune-competent syngeneic tumor mouse model to evaluate the strategy’s effectiveness . Co-culturing CARIR-expressing human monocytic THP-1 cells with PD-L1 target cells lead to upregulation of the co-stimulatory molecule CD86 along with expression of proinflammatory cytokines TNF-1α and IL-1β. Moreover, CARIR expression significantly enhanced phagocytosis of multiple PD-L1 human solid tumor cell lines . Similar outcomes were observed with CARIR-expressing human primary macrophages. In experiments conducted on Balb/c mice bearing aggressive 4T1 mammary tumors, infusing murine myeloid cells expressing a murine version of CARIR significantly slowed tumor growth and prolonged survival. Taken together, our results demonstrate that adoptive transfer of PD-1 CARIR-engineered myeloid cells may be an effective strategy in treating PD-L1 solid tumors.

Immunology

What problem does this paper attempt to address?

This paper mainly discusses how to use marrow cells expressing chimeric antigen receptors of immune receptors (CARIRs) to treat solid tumors. In solid tumors, myeloid cells such as macrophages often exhibit phenotypes that promote tumor growth, hindering the effectiveness of immunotherapy. The researchers designed a CARIR with the extracellular domain derived from the natural inhibitory receptor PD-1 and the intracellular domain derived from CD40 and/or CD3x. Through in vitro experiments and in vivo mouse models, they demonstrated that marrow cells expressing CARIR can enhance phagocytosis of PD-L1-positive tumor cells and significantly slow down tumor growth and prolong survival in a 4T1 mouse model of breast cancer. Therefore, this study proposes the use of CARIR-engineered marrow cells as a potential strategy for treating PD-L1-positive solid tumors.